Cancers of the oral cavity and oropharynx: FDG PET with contrastenhanced CT in the posttreatment setting

Radiographics

Volumn 31, Issue 2, 2011, Pages 355-373

  King, Kevin G ^a   Kositwattanarerk, Arpakorn ^a   Genden, Eric ^a   Kao, Johnny ^a   Som, Peter M ^a   Kostakoglu, Lale ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMAGE QUALITY; IMAGE SUBTRACTION; METHODOLOGY; MOUTH TUMOR; OROPHARYNX TUMOR; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT OUTCOME;

CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; HUMANS; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOGRAPHIC IMAGE ENHANCEMENT; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79953805466     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.312095765     Document Type: Article

References (80)

1. Pfister DG, Ang KK, Brazel D, et al. Head and neck cancers. In: NCCN clinical practice guidelines in oncology. Fort Washington, Pa: National Comprehensive Cancer Network, 2010.
2. Close L, Larson DL, Shah JP. Essentials of head and neck oncology. New York, NY: Thieme, 1998.
3. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18FFDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 2004;45(suppl 1): 56S-65S.
4. Edge SB, Compton, CC; for the American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York, NY: Springer, 2010.
5. Cohan DM, Popat S, Kaplan SE, Rigual N, Loree T, Hicks WL Jr. Oropharyngeal cancer: current understanding and management. Curr Opin Otolaryngol Head Neck Surg 2009;17(2):88-94.
6. Osborne RF, Brown JJ. Carcinoma of the oral pharynx: an analysis of subsite treatment heterogeneity. Surg Oncol Clin N Am 2004;13(1):71-80.
7. Lin DT, Cohen SM, Coppit GL, Burkey BB. Squamous cell carcinoma of the oropharynx and hypopharynx. Otolaryngol Clin North Am 2005;38(1): 59-74, viii.
8. Bailey BJ, Johnson JT, Newlands SD. Head & neck surgery-otolaryngology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2006.
9. Scully C, Bagan JV. Recent advances in Oral Oncology 2007: imaging, treatment and treatment outcomes. Oral Oncol 2008;44(3):211-215.
10. Yao M, Epstein JB, Modi BJ, Pytynia KB, Mundt AJ, Feldman LE. Current surgical treatment of squamous cell carcinoma of the head and neck. Oral Oncol 2007;43(3):213-223.
11. Lee NY, Terezakis SA. Intensity-modulated radiation therapy. J Surg Oncol 2008;97(8):691-696.
12. Lee N, Puri DR, Blanco AI, Chao KS. Intensitymodulated radiation therapy in head and neck cancers: an update. Head Neck 2007;29(4):387-400.
13. Caglar HB, Allen AM. Intensity-modulated radiotherapy for head and neck cancer. Clin Adv Hematol Oncol 2007;5(6):425-431.
14. Biel MA. Photodynamic therapy and the treatment of head and neck neoplasia. Laryngoscope 1998;108 (9):1259-1268.
15. Biel MA. Photodynamic therapy of head and neck cancers. Methods Mol Biol 2010;635:281-293.
16. Hopper C, Kübler A, Lewis H, Tan IB, Putnam G. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer 2004; 111(1):138-146.
17. Lou PJ, Jäger HR, Jones L, Theodossy T, Bown SG, Hopper C. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer 2004;91(3):441-446.
18. Hermans R. Posttreatment imaging in head and neck cancer. Eur J Radiol 2008;66(3):501-511.
19. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110(3 pt 2 suppl 93): 1-18.
20. Richey LM, Shores CG, George J, et al. The effectiveness of salvage surgery after the failure of primary concomitant chemoradiation in head and neck cancer. Otolaryngol Head Neck Surg 2007;136(1): 98-103.
21. Wong RJ, Lin DT, Schöder H, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20(20):4199-4208.
22. Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 2003;25 (11):953-959.
23. Yom SS, Machtay M, Biel MA, et al. Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx. Am J Clin Oncol 2005;28(4): 385-392.
24. Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol 2008;97(8):649-652.
25. Gupta T, Jain S, Agarwal JP, et al. Diagnostic performance of response assessment FDG-PET/CT in patients with head and neck squamous cell carcinoma treated with high-precision definitive (chemo) radiation. Radiother Oncol 2010;97(2):194-199.
26. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000;110(9):1493-1497.
27. Ong SC, Schöder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008;49 (4):532-540.
28. Kubota K, Yokoyama J, Yamaguchi K, et al. FDGPET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004;31(4):590-595.
29. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33(3):210-222.
30. Greven KM, Williams DW 3rd, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001;23(11):942-946.
31. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34(5):773-779.
32. Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med 2006; 47(4):603-608.
33. Kutler DI, Wong RJ, Schoder H, Kraus DH. The current status of positron-emission tomography scanning in the evaluation and follow-up of patients with head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2006;14(2):73-81.
34. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005;63(4): 991-999.
35. Tan A, Adelstein DJ, Rybicki LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2007;133(5):435-440.
36. Martin RC, Fulham M, Shannon KF, et al. Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head Neck 2009;31 (2):244-250.
37. Schöder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009;50(suppl 1): 74S-88S.
38. Lango MN, Myers JN, Garden AS. Controversies in surgical management of the node-positive neck after chemoradiation. Semin Radiat Oncol 2009;19(1): 24-28.
39. Malone J, Robbins KT. Neck dissection after chemoradiation for carcinoma of the upper aerodigestive tract: indications and complications. Curr Opin Otolaryngol Head Neck Surg 2010;18(2): 89-94.
40. Chen AY, Vilaseca I, Hudgins PA, Schuster D, Halkar R. PET-CT vs contrast-enhanced CT: what is the role for each after chemoradiation for advanced oropharyngeal cancer? Head Neck 2006;28 (6):487-495.
41. Dalsaso TA, Lowe VJ, Dunphy FR, Martin DS, Boyd JH, Stack BC. FDG-PET and CT in evaluation of chemotherapy in advanced head and neck cancer. Clin Positron Imaging 2000;3(1):1-5.
42. Ojiri H, Mendenhall WM, Stringer SP, Johnson PL, Mancuso AA. Post-RT CT results as a predictive model for the necessity of planned post-RT neck dissection in patients with cervical metastatic disease from squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2002;52(2):420-428.
43. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. Head Neck 2005;27(3):175-181.
44. Goguen LA, Posner MR, Tishler RB, et al. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132 (5):526-531.
45. Inohara H, Enomoto K, Tomiyama Y, et al. The role of CT and (18)F-FDG PET in managing the neck in node-positive head and neck cancer after chemoradiotherapy. Acta Otolaryngol 2008 Oct 7:1-7.
46. Nayak JV, Walvekar RR, Andrade RS, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PETCT. Laryngoscope 2007;117(12):2129-2134.
47. Rabalais AG, Walvekar R, Nuss D, et al. Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy. Laryngoscope 2009;119(6):1120-1124.
48. Ware RE, Matthews JP, Hicks RJ, et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck 2004;26(12):1008-1017.
49. Yao M, Luo P, Hoffman HT, et al. Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment. Am J Clin Oncol 2007;30(3):264-270.
50. Gourin CG, Boyce BJ, Williams HT, Herdman AV, Bilodeau PA, Coleman TA. Revisiting the role of positron-emission tomography/computed tomography in determining the need for planned neck dissection following chemoradiation for advanced head and neck cancer. Laryngoscope 2009;119(11): 2150-2155.
51. Rogers JW, Greven KM, McGuirt WF, et al. Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys 2004;58(3):694-697.
52. Schöder H, Carlson DL, Kraus DH, et al. 18FFDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47(5): 755-762.
53. Fleming AJ Jr, Smith SP Jr, Paul CM, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007;117(7):1173-1179.
54. Gourin CG, Williams HT, Seabolt WN, Herdman AV, Howington JW, Terris DJ. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope 2006;116(5):705-710.
55. Richards PS, Peacock TE. The role of ultrasound in the detection of cervical lymph node metastases in clinically N0 squamous cell carcinoma of the head and neck. Cancer Imaging 2007;7:167-178.
56. Takes RP, Knegt P, Manni JJ, et al. Regional metastasis in head and neck squamous cell carcinoma: revised value of US with US-guided FNAB. Radiology 1996;198(3):819-823.
57. van den Brekel MW, Castelijns JA, Stel HV, et al. Occult metastatic neck disease: detection with US and US-guided fine-needle aspiration cytology. Radiology 1991;180(2):457-461.
58. Wensing BM, Merkx MA, De Wilde PC, Marres HA, Van den Hoogen FJ. Assessment of preoperative ultrasonography of the neck and elective neck dissection in patients with oral squamous cell carcinoma. Oral Oncol 2010;46(2):87-91.
59. Abgral R, Querellou S, Potard G, et al. Does 18FFDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50(1):24-29.
60. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994;73(1):187-190.
61. Kao J, Vu HL, Genden EM, et al. The diagnostic and prognostic utility of positron emission tomography/ computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer 2009;115(19):4586-4594.
62. Wang YF, Liu RS, Chu PY, et al. Positron emission tomography in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy. Head Neck 2009;31(4):442-451.
63. Subramaniam RM, Truong M, Peller P, Sakai O, Mercier G. Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer. AJNR Am J Neuroradiol 2010;31(4): 598-604.
64. Agarwal V, Branstetter BF 4th, Johnson JT. Indications for PET/CT in the head and neck. Otolaryngol Clin North Am 2008;41(1):23-49, v.
65. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004;15(8):1179-1186.
66. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937-1944.
67. Stambuk HE, Karimi S, Lee N, Patel SG. Oral cavity and oropharynx tumors. Radiol Clin North Am 2007;45(1):1-20.
68. Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K, Schwaiger M. Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol 2009;2009:208725.
69. Bui CD, Ching AS, Carlos RC, Shreve PD, Mukherji SK. Diagnostic accuracy of 2-[fluorine-18]fluro-2-deoxy-D-glucose positron emission tomography imaging in nonsquamous tumors of the head and neck. Invest Radiol 2003;38(9):593-601.
70. Weber AL, Romo L, Hashmi S. Malignant tumors of the oral cavity and oropharynx: clinical, pathologic, and radiologic evaluation. Neuroimaging Clin N Am 2003;13(3):443-464.
71. Jabour BA, Choi Y, Hoh CK, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993;186(1):27-35.
72. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. RadioGraphics 2004;24(5):1411-1431.
73. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake-the role of PET/ CT. Eur Radiol 2006;16(5):1054-1065.
74. Blodgett TM, Fukui MB, Snyderman CH, et al. Combined PET-CT in the head and neck. I. Physiologic, altered physiologic, and artifactual FDG uptake. RadioGraphics 2005;25(4):897-912.
75. Chung JH, Cho KJ, Lee SS, et al. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging. J Nucl Med 2004;45(6):999-1003.
76. Jones RG, Thompson CB. Revving the engine: signal transduction fuels T cell activation. Immunity 2007;27(2):173-178.
77. Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol 2008;84(4):949-957.
78. Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg 2009;67(5 suppl):75-84.
79. Curi MM, Oliveira dos Santos M, Feher O, Faria JC, Rodrigues ML, Kowalski LP. Management of extensive osteoradionecrosis of the mandible with radical resection and immediate microvascular reconstruction. J Oral Maxillofac Surg 2007;65(3): 434-438.
80. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29(8): 1548-1558.